DRUG-INDUCED LUPUS ERYTHEMATOSUS

Medicinal or drug-induced lupus erythematosus (DIL) is an autoimmune phenomenon, which is clinically and morphologically similar to idiopathic lupus erythematosus, that occurs in patients during the long-term use of drugs, the list of which currently includes more than 100 items. To date, the pathogenesis of DIL has not been fully deciphered, and diagnostic criteria have not been developed, which determines the difficulties of diagnosis and determination of therapeutic approaches. At the same time, the widespread introduction of new classes of drugs, in particular, TNF inhibitors and other genetically engineered biological drugs associated with the risk of developing a systemic form of DIL, the use of proton pump inhibitors and chemotherapy drugs that induce subacute lupus erythematosus, allow predicting an increase in the prevalence of DIL, including in children, which in its turn determines the relevance of the problem of DIL in pediatric practice. This bibliographical review summarizes the current data on drugs that are potential inducers of DIL, possible mechanisms of development and clinical forms of the disease, principles of diagnosis and therapy.